Chloroquine (CQ) is a weak base that was originally used to treat malaria infection.1 However, recent findings have pinpointed the modulatory effect of CQ in models of chronic inflammation and viral infections. The antiviral effect of CQ and its derivative hydroxychloroquine has attracted great attention due to the recent Sars-CoV-2 virus outbreak.2,3 As an immunomodulatory agent, CQ reduces the severity of experimental autoimmune encephalomyelitis (EAE), likely by inducing regulatory T cells and tolerogenic dendritic cells (DCs).4,5 EAE and multiple sclerosis (MS) are demyelinating disorders of the CNS in which interleukin (IL)-17-producing helper T (Th17) cells play a major role in disease severity. To date, there has been no report of the effect of CQ on T cell differentiation; thus, we aimed to investigate whether CQ interferes with Th17 cell differentiation.
We isolated CD4+ T cells from the spleens of wild-type (WT) C57BL/6 mice and activated the cells with agonistic anti-CD3/CD28 antibodies under Th17 polarizing conditions in the presence or absence of CQ. We found that cultures with CQ had a significant decrease in IL-17 production (Fig. 1a). Moreover, CQ at low concentrations was toxic to Th17 cells but not to Th1 cells or DCs (Fig. 1b). Indeed, CQ augmented Th1 cell differentiation (Fig. 1b). These results show that Th17 cells are more susceptible to CQ toxicity than Th1 cells and DCs. We then investigated whether CQ also impacts Tc17 cell differentiation and found that IL-17 production by CD8+ T cells was also reduced by CQ treatment (Fig. 1c). Because T-bet and STAT1 are major suppressors of Th17 cell differentiation,6,7 we aimed to investigate T-bet and STAT1 expression in CQ-treated cells. Cultures of CQ-treated Th17 cells with the least toxic dose of CQ had a significant increase in T-bet but not STAT1 expression (Fig. 1d). This result is interesting because we recently showed that CQ-induced tolerogenic DCs rely on STAT1 expression to maintain their suppressive function.8 Collectively, our current results indicate that, in T cells, CQ suppresses Th17 cell differentiation by stimulating T-bet rather than STAT1 expression.
Finally, we investigated whether EAE suppression in CQ-treated mice is associated with an increase in T-bet expression in Th17 cells. We immunized WT mice with MOG35-55 peptide in complete Freund’s adjuvant to induce EAE and monitored the mice daily for disease development. CQ treatment started once the mice showed the first signs of EAE (approximately day 10 p.i.) and continued for 7 consecutive days. Similar to what we previously published,4 CQ-treated mice displayed significantly less severe EAE than PBS-treated mice (Fig. 1e). Analysis of CNS cells at day 21 p.i. revealed that CQ-treated mice had a significant decrease in IL-17-producing Th17 cells and no effect on IFN-γ-producing Th1 cells compared with cells from PBS-treated mice (Fig. 1f). Further analyses showed that STAT1 expression was unchanged, while T-bet expression was increased in Th17 cells in the CNS of CQ-treated mice compared with those treated with PBS (Fig. 1g).
Collectively, our results demonstrate a novel mechanism by which CQ reduces inflammation in EAE through inducing T-bet expression in T cells and reducing Th17 differentiation. Interestingly, the shift in the balance between Th17/Th1 cells towards IFN-γ production may reflect another pathway by which CQ augments antiviral responses. Nevertheless, further studies are necessary to confirm this hypothesis. Our results provide further evidence that CQ may be a powerful therapeutic agent in MS and the other chronic inflammatory diseases of the CNS.
References
Thome, R., Lopes, S. C., Costa, F. T. & Verinaud, L. Chloroquine: modes of action of an undervalued drug. Immunol. Lett. 153, 50–57 (2013).
Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).
Zhou, D., Dai, S. M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. dkaa114, https://doi.org/10.1093/jac/dkaa114 (2020).
Thome, R. et al. Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PLoS ONE 8, e65913 (2013).
Thome, R. et al. Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. Immunol. Cell Biol. 92, 124–132 (2014).
Villarino, A. V., Gallo, E. & Abbas, A. K. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J. Immunol. 185, 6461–6471 (2010).
Lazarevic, V. et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nat. Immunol. 12, 96–104 (2011).
Thome, R. et al. Chloroquine-treated dendritic cells require STAT1 signaling for their tolerogenic activity. Eur. J. Immunol. 48, 1228–1234 (2018).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thome, R., Boehm, A., Ishikawa, L.L.W. et al. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells. Cell Mol Immunol 18, 779–780 (2021). https://doi.org/10.1038/s41423-020-0432-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-020-0432-9